InstalabLoading...
InstalabLoading...
Your immune system has two main fighting forces. One handles infections directly, the other makes antibodies that stick to invaders and flag them for destruction. This test counts the cells in that second force, the B lymphocytes, using a surface marker called CD19 that sits on nearly every one of them.
A normal complete blood count will not tell you this number. You can have a perfectly normal lymphocyte count and still have profoundly low or abnormally shifted B cells hiding underneath. For anyone on immune-modulating therapy, recovering from a serious infection, or dealing with an autoimmune condition, this is often the number that actually matters.
CD19 (a surface protein found on nearly all B cells) is the marker labs use to identify and count B lymphocytes by flow cytometry, a technique that sorts cells by what sits on their surface. The test reports an absolute count of how many CD19-positive B cells are circulating per microliter of your blood.
B cells are made in your bone marrow, then circulate through blood to populate your lymph nodes and spleen. Their job is humoral immunity, which is the antibody-based arm of your defense system. When B cells encounter something foreign, they mature into plasma cells that pump out antibodies tailored to that specific threat. Once they become fully differentiated plasma cells, they typically lose CD19, so this test captures B cells at most stages except the final antibody-secreting one.
A percentage can look normal while the underlying number is badly off. In Parkinson disease, systematic review evidence shows absolute CD19-positive B cells are significantly decreased compared with controls even when percentages appear normal. Always anchor interpretation on the absolute count.
The strongest hard-outcome data for this biomarker come from kidney disease. In a prospective cohort of 104 hemodialysis patients followed for a median of 18 months, people whose CD19-positive count was below 100 cells per microliter had a 60-month survival rate of roughly 16 percent, compared with 54 percent in those above that threshold.
After adjusting for age, prior cardiovascular disease, Charlson comorbidity score, and dialysis adequacy, low B cells remained an independent predictor of death. For cardiovascular mortality specifically, being below 100 cells per microliter was associated with roughly 4 times the risk (hazard ratio 4.1, 95% confidence interval 1.2 to 14.6) after adjusting for age, ischemic heart disease, and comorbidity burden.
In advanced chronic kidney disease, lower B-cell counts also track with worse cardiac remodeling. End-stage renal disease patients starting dialysis showed a median CD19-positive count of about 71 cells per microliter, compared with 171 in healthy controls, roughly 60 percent lower.
In HPV-associated head and neck and cervical cancers analyzed from the Cancer Genome Atlas (over 800 patients), tumors with higher CD19 expression (more B-cell infiltration) predicted substantially better survival. Three-year overall survival was roughly 45 percent higher in the CD19-high group compared with CD19-low (hazard ratio 0.545, 95% confidence interval 0.41 to 0.72).
In a gastric cancer cohort of 291 post-surgical patients followed up to 5 years, a composite of CD19-positive B cell count with the Prognostic Nutritional Index stratified outcomes, with the lower-composite group showing significantly worse progression-free and overall survival.
If you are on anti-CD20 therapy like rituximab or ocrelizumab for multiple sclerosis, neuromyelitis optica, lupus, rheumatoid arthritis, or another autoimmune condition, this number is how you know whether your treatment is actually working at the cellular level. These drugs deliberately wipe out B cells. In a French MS cohort on long-term anti-CD20 therapy, about 86 percent of patients showed sustained CD19-positive depletion at 18 months.
In MS and NMOSD, CD19-positive repopulation timing guides when to dose the next infusion. A threshold of 10 or more CD19-positive cells per microliter has been used to define suboptimal depletion, which associates with disability progression independent of relapses. Dose matters, but only up to a point. Lower rituximab doses (250 mg) allow faster B-cell return (around 6.4 months), while higher doses (500 to 1000 mg) extend the depletion window to 9 to 15 months. Doses above 1000 mg showed no added benefit, suggesting a ceiling effect.
For people treated with CD19-targeted CAR-T cell therapy for B-cell leukemia or lymphoma, sustained B-cell aplasia (a near-zero B-cell count) is actually a good sign. It shows the CAR-T cells are still working. In pediatric and young adult acute lymphoblastic leukemia treated with tisagenlecleucel, loss of B-cell aplasia correlated strongly with CD19-positive relapse.
The flip side is infection risk. In a retrospective analysis of 579 adults receiving CD19 CAR-T, median B-cell aplasia lasted 237 days, and 91 percent developed low antibody levels (hypogammaglobulinemia). Post-CAR-T hypogammaglobulinemia was linked to serious infections, with an incidence rate ratio of 2.7 (95% confidence interval 1.5 to 5.2). Mortality also rose with mild hypogammaglobulinemia and early infections.
In newly diagnosed HIV, lower B-cell counts correlate with higher viral load and more advanced disease. A CD19-positive count below roughly 167 cells per microliter contributed to identifying AIDS stage, with 63.6 percent sensitivity and 65.4 percent specificity. CD3-positive T cells outperformed B cells as a standalone staging tool (91.4 percent sensitivity), but B-cell counts add complementary information about humoral immune damage.
The story in autoimmunity is less about total numbers and more about which B-cell subsets are expanded. In systemic lupus erythematosus, a subtype called double-negative 3 B cells tracks disease activity in women, and CD19 expression level itself serves as a biomarker. In rheumatoid arthritis, higher frequencies of regulatory CD19-positive CD24-high CD38-high transitional B cells predict better response to methotrexate at 12 months.
In chronic graft-versus-host disease after bone marrow transplant, elevated CD19-positive CD21-low B cells above 9 percent strongly predicts bronchiolitis obliterans syndrome, a serious lung complication.
Adult reference ranges vary between labs and populations. The values below come primarily from a multiple sclerosis reference cohort and a healthy Chinese adult cohort. They are orientation, not universal targets. Your lab will likely report its own reference interval, and you should compare your results within the same lab over time.
| Context | Approximate Absolute CD19+ Count | What It Suggests |
|---|---|---|
| Healthy adults (CD19+CD20+) | 86 to 595 cells/µL (mean ~275) | Normal B-cell compartment |
| MS reference values | 100 to 800 cells/µL | Used for baseline interpretation in MS monitoring |
| Hemodialysis cutoff for elevated mortality risk | Below 100 cells/µL | Independently predicts higher all-cause and cardiovascular death |
| Anti-CD20 therapy target | Below 10 cells/µL | Effective depletion; above this suggests suboptimal response |
Source: Ellrichmann et al. (MS reference range), Feng et al. (healthy Chinese adults), Molina et al. (hemodialysis mortality threshold), Revie et al. (anti-CD20 suboptimal depletion threshold).
B-cell counts peak in infancy and decline steadily through childhood and adolescence. In a study of 813 children aged 0 to 18, absolute B cells were highest between 2 and 12 months of age, then gradually decreased. If you are looking at pediatric results, always match them to age-specific reference intervals from the reporting lab.
Several medications can dramatically shift your B-cell count without telling you anything about a new problem. If you are on any of the following, your number will reflect the drug, not your baseline immune status.
A single B-cell count is a snapshot. The real value of this test comes from watching it move over time. If you are on rituximab, ocrelizumab, or a similar B-cell depleting drug, retesting at 3 to 6 month intervals tells you whether depletion is holding or whether B cells are returning faster than expected, which can inform when to redose. In MS, CD19-positive repopulation timing is the actual clinical anchor for infusion intervals, not just the calendar.
If you have autoimmune disease, CAR-T therapy history, advanced kidney disease, or HIV, a baseline now and a follow-up in 3 to 6 months gives you a trajectory to compare against. After that, at least annual monitoring is reasonable if you are stable, more frequent if you are making treatment changes.
A low absolute B-cell count in someone on B-cell depleting therapy is expected and usually reassuring. A low count in someone not on such therapy warrants follow-up. Companion tests that add clinical information include serum immunoglobulins (IgG, IgA, IgM) to see whether antibody production is also affected, CD4 and CD8 T-cell counts to map the broader immune picture, a natural killer (NK) cell count for a full lymphocyte subset profile, and, depending on context, kidney function tests (eGFR, cystatin C), HIV viral load, or specific autoimmune antibodies.
An unexplained low count that persists on retest is worth discussing with a clinical immunologist or hematologist, particularly if you have recurrent infections. An unexplained high count, especially with unexplained lymphocytosis on a standard CBC, warrants evaluation for B-cell proliferative disorders. In asymptomatic patients with lymphocytosis, CD19 counts are roughly 98 percent sensitive for detecting B-cell chronic lymphoproliferative disorders, making it a useful screening step.
Evidence-backed interventions that affect your Absolute B Cells (CD19+) level
Absolute B Cells (CD19+) is best interpreted alongside these tests.